FoundationOne™, the first clinical product from Foundation Medicine, is a fully informative genomic profile that complements traditional cancer treatment decision tools and often expands treatment options by matching each patient with targeted therapies that are relevant to the molecular changes in their tumor.
FoundationOne is the first commercially available targeted sequencing assay utilizing clinical grade next-generation sequencing (NGS) in routine cancer specimens. This test identifies all classes of genomic alterations (including copy number alterations, insertions, deletions and rearrangements) in hundreds of cancer-related genes. FoundationOne's genomic profile results are reported to the physician and matched with targeted therapies and clinical trials that may be relevant to each individual patient based on the most recent scientific and medical research.
- FoundationOne Test Requisition Form
- Specimen Preparation Instructions
- Billing Guidelines for Medical Practices
- Billing Guidelines for Patients and Caregivers
- Technical Information and Test Overview (Current as of Dec. 31, 2012)
- Current Gene List
About Foundation Medicine
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which individual patient treatment is informed by a deep understanding of the genomic changes that contribute to that patient’s unique cancer. The company has developed a fully informative genomic profile to identify a patient’s individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit our corporate website at foundationmedicine.com.
For career opportunities at Foundation Medicine, please visit our Careers page.
Thank you for your interest in FoundationOne. Here are links to a number of resources for background information:
- Download our corporate fact sheet for quick facts
- Visit our corporate website for questions about Foundation Medicine and recent press releases
- Watch an animated guide to FoundationOne or a quick video about Foundation Medicine
Please contact Caton Lovett at Pure Communications for additional questions.
Associate Director, Client Service
Pure Communications, Inc.
Office: (919) 787-7159
In the News
April 28, 2013 - Variations on a Gene, and Tools to Find Them | New York Times
January 19, 2013 - Biotech Catches the Eye of Bill Gates | Wall Street Journal
December 29, 2012 - The Future of Medicine is Now | Wall Street Journal
October 31, 2012 - Design Firms Go Beyond Gadgets as Portfolios Expand | Wall Street Journal
October 25, 2012 - Alexis Borisy: Transforming the Fight Against Cancer with Big Data (Video)
October 12, 2012 - Big Data May Yield Cancer Breakthroughs | CNBC
September 19, 2012 - FierceBiotech Names Foundation Medicine as One of 2012’s Fierce 15
September 12, 2012 - New Cancer Drugs Are Showing Great Promise | U.S. News and World Reports
May 30, 2012 – Foundation Medicine Launches FoundationOne™
May 25, 2012 - New cancer test at Norwalk Hospital could prove key
- Ross JS, Wang K, Sheehan CE, Boguniewicz AB, Otto G, Downing SR, Sun J, He J, Curran JA, Ali S, Yelensky R, Lipson D, Palmer G, Miller VA, Stephens PJ. Relapsed classic E-cadherin (CDH1) mutated invasive lobular breast cancer demonstrates a high frequency of HER2 (ERBB2) gene mutations. Clinical Cancer Research. 30 April 2013. Abstract.
- Vignot S, Frampton GM, Soria JC, Yelensky R, Commo F, Brambilla C, Palmer G, Moro-Sibilot D, Ross JS, Cronin MT, André F, Stephens PJ, Lazar V, Miller VA, Brambilla E. Next-Generation Sequencing Reveals High Concordance of Recurrent Somatic Alterations Between Primary Tumor and Metastases From Patients With Non-Small-Cell Lung Cancer. Journal of Clinical Oncology. 29 April 2013. Abstract.
Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens PJ, Ross J, Miller VA, Ginsberg MS, Zakowski MF, Kris MG, Ladanyi M, Rizvi NA. Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas. Cancer Discovery. 2013 Mar 26. [Epub ahead of print]
Beltran H, et al. (2012) Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity. Eur Urol, http://dx.doi.org/10.1016/j.eururo.2012.08.053
- Peled N, Palmer G, Hirsch F, et al. (2012) Next
Generation Sequencing Identifies and Immunohistochemistry Confirms
a Novel Crizotinib Sensitive ALK Rearrangement in a Patient with
Metastatic Non-small Cell Lung Cancer. J Thoracic
2012 Sep; 7(9):e14-6. (DOI: 10.1097/JTO.0b013e3182614ab5).
- Capelletti M, Yelensky R, et al. (2012) Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nature Medicine 18, 382-384.
- Cronin M, Ross JS. (2011) Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology. Biomark Med. (3):293-305.
- Miller V, “Clinical applications of comprehensive genotyping in solid tumors: Obstacles and opportunities”, AACR 2012 Presentation.
- Ross JS, Parker A, Jarosz M, Downing S, et al. Massively Parallel Sequencing in NSCLC: Comparison to Traditional Hot Spot Analysis for Selection of Approved and Novel Targeted Therapies. Modern Pathol 2012; 25(suppl2): 488A. Oral presentation.
- Palmer G, Miller V, Curran J, et. al. Next-generation sequencing (NGS) reliably identifies actionable genomic changes in common and rare solid tumors: The FMI experience with the initial 50 consecutive patients [abstract]. In: Proceedings of the 2012 American Society of Clinical Oncology Annual Meeting; 2012 Jun 1-5; Chicago, Illinois. ASCO; 2012. Abstract nr 10590. View Poster.
- Jarosz M, Juhn F, Brannan K, et al. Comprehensive Next-Generation Sequencing From Formalin Fixed Tissue Representing a Range of Specimen Ages and Tissue Types [abstract]. Presented at Association for Molecular Pathology Meeting 2011. View poster.
Lipson D, He J, Yelensky R, Miller V, Sheehan C, Brennan K, Stephens P, Cronin M, Ross J. Next-generation sequencing of FFPE breast cancers demonstrates high concordance with FISH in calling HER2 amplifications and commonly identifies additional clinically relevant genomic alterations. Presented at CTRC-AACR San Antonio Breast Cancer Symposium 2012. View poster.